Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
A single-site study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine therapy, in metastatic breast cancer patients with HR-positive \& HER2-negative after capecitabine-base chemotherapy.
Breast Cancer
DRUG: Capecitabine|DRUG: endocrine therapy
Progression-free survival(PFS), Progression-free survival (PFS) is defined as the time elapsed between enrolling and tumor progression or death from any cause, From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
clinical benefit rate(CBR), the response is CR+PR+SD ≥ 24 weeks, From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years|overall survival, the time elapsed between enrolling and death from any cause, From date of enrolling until the date of death from any cause, assessed up to 3 years|Number of participants with Grade 3/4 adverse events, Number of Participants with Grade 3/4 Adverse Events, From date of enrolling until the date of 1 month of stop treatment, assessed up to 3 years|Quality of life(QOL)（1）, change from enrolling to progression disease or death according EORTC QLQ-C30, From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years|Quality of life(QOL)（2）, change from enrolling to progression disease or death according EORTC BR23, From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
Capecitabine-base chemotherapy must be ≥Second-line Therapy